Navigation Links
New 'implanted contacts' designed to fix nearsightedness

UT Southwestern Medical Center ophthalmologists will be the first in the area to insert a new type of implanted lens to fix nearsightedness.

"Think of it as a contact lens inside your eye," said Dr. Wayne Bowman, who is inserting the new implantable collamer lens, or ICL, today for the first time at UT Southwestern University Hospitals.

The ICL can replace or reduce the need for glasses by permanently placing the specially fitted artificial lens in front of the eye's natural lens, rather than replacing the natural lens as other implanted lens do, said Dr. Bowman, professor of ophthalmology.

The lens, made of a special collamer material, corrects moderate to severe nearsightedness, known as myopia, by bending light rays to improve blurry distance vision without the need for glasses or contacts.

Dr. Bowman said the lens currently is approved only for nearsightedness, but it may eventually be available for farsightedness and astigmatism. It has been used for nearsightedness for several years in Europe and was approved by the Food and Drug Administration in December.

According to the FDA, a clinical study of 294 implanted patients showed that 95 percent ?279 patients ?had 20/40 or better vision, which is considered the standard needed for an unrestricted driver's license. And 59 percent ?almost 175 patients ?had 20/20 or better vision after three years.

Ideal candidates are typically under 40 years of age and don't yet have presbyopia, which makes reading glasses necessary, and whose corrections are outside the parameters for routine laser procedures, said Dr. Steven Verity, associate professor of ophthalmology, who specializes in refractive corneal surgery.

Rather than reshaping the eye, as in laser surgery, or replacing the eye's natural lens, as with intraocular lenses, the collamer lens is inserted with a smaller incision. Th e lens is like a fixed contact, but it can be removed if need be.

The procedure, Dr. Bowman said, normally takes about 10 to 15 minutes, and the patient sees the improvement soon after.


'"/>

Source:UT Southwestern Medical Center


Related biology news :

1. Medical molecules designed to respond to visible light that can penetrate tissue
2. Redesigned protein accelerates blood clotting
3. Intelligently designed molecular evolution
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016  Mosaic Biomedicals ... el desarrollo acelerado de MSC-1, un anticuerpo humanizado que se espera ... en 2017, con múltiples sitios previstos a lo largo de Europa ... MSC-1 ... factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que se sobreexpresa ...
(Date:12/15/2016)... FREMONT, Calif. , Dec. 15, 2016   ... a publicly held genomics technology company, announced today that ... the Listing Qualifications Department of The Nasdaq Stock Market ... the closing bid price of WaferGen,s common stock had ... days.  Accordingly, WaferGen has regained compliance with Listing Rule ...
(Date:12/12/2016)... Dec. 12, 2016  Researchers at Trinity College, ... graphene by combining the material with Silly Putty. The ... pressure detector able to sense pulse, blood pressure, ... spider.  The research team,s findings ... read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... replacement at the Caribbean Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica ... technology and host a hands-on workshop for surgeons to experience the simplicity of ...
(Date:1/21/2017)... , ... January 21, 2017 , ... ... endeavors to bring to market a pioneering medical device for the treatment of ... an engagement contract with Emergo, a global regulatory consultancy that helps companies like ...
(Date:1/21/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, today presented data from two clinical ... 2017 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers ... In a Phase Ib/II study of napabucasin ... cancer stemness pathways by targeting STAT3 – colorectal cancer ...
(Date:1/20/2017)... NEW YORK , January 20, 2017 ... Health Organization, cancer is one of leading causes of ... in 2012. Although the number of cancer related deaths ... since 1990. Rising in incidence rate of various cancers ... According to a research report by Global Market Insights, ...
Breaking Biology Technology: